Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

ODTX earnings analysis

Filed June 17, 2026 · Our reading of the company's report

The latest report

Odyssey Therapeutics, Inc. reported a net loss of $38.3 million for Q1 2026, a slight improvement compared to the $38.4 million loss a year earlier. Revenue was reported as zero for the quarter, compared to $1.9 million…

Read full summary

Odyssey Therapeutics, Inc. reported a net loss of $38.3 million for Q1 2026, a slight improvement compared to the $38.4 million loss a year earlier. Revenue was reported as zero for the quarter, compared to $1.9 million from partnership agreements in Q1 2025. Key progress includes the achievement of clinical proof-of-concept for their oral RIPK2 inhibitor OD-001 in ulcerative colitis, alongside maintaining a strong cash position of approximately $175.7 million, projected to fund operations into late 2028.

Read the original on SEC.gov

What stood out

  • Improvement in Net Loss

    Net loss improved slightly to $38.3 million in Q1 2026 from $38.4 million in Q1 2025.

  • Strong Cash Position

    Cash, cash equivalents, and marketable securities totaled $175.7 million as of March 31, 2026.

  • Clinical Proof-of-Concept Achieved

    Achieved proof-of-concept for OD-001 in a trial for moderate to severe ulcerative colitis.

  • Reduced R&D Expenses

    Research and development expenses decreased by $6.5 million to $32.3 million from $38.8 million year-over-year.

  • Positive Cash Flow from Investing Activities

    Net cash provided by investing activities reached approximately $34.8 million.

  • Increased Interest Income

    Interest income rose to $1.7 million from $1.2 million year-over-year.

What to watch

  • No Revenue Generation

    The company reported zero revenue for Q1 2026, down from $1.9 million from collaborations in Q1 2025.

  • Continuous Operating Losses

    Firm has incurred significant net losses, with an accumulated deficit of $606.4 million as of March 31, 2026.

  • Dependence on Third-Party Manufacturers

    Reliance on external manufacturers poses risks related to compliance and dependency on their capabilities.

Management's outlook

The company anticipates continued R&D expense increases but does not provide explicit guidance on revenue or EPS.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.